SCHEMBL4140693

SCHEMBL4140693

CCOC(=O)Cc1ccc(O)c(O)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
YWHAG P61981 1/20 0.68
GAA P10253 2/20 0.56
NFKB1 P19838 2/20 0.56
MAPT P10636 2/20 0.56
KDM4E B2RXH2 1/20 0.56
RGS12 O14924 1/20 0.56
LMNA P02545 1/20 0.56
POLB P06746 1/20 0.56
HPGD P15428 1/20 0.56
TSHR P16473 1/20 0.56
APEX1 P27695 1/20 0.56
THPO P40225 1/20 0.56
BLM P54132 1/20 0.56
GNAI1 P63096 1/20 0.56
PMP22 Q01453 1/20 0.56
HIF1A Q16665 1/20 0.56
HSD17B10 Q99714 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
CA1 P00915 2/20 0.54
CA2 P00918 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31741653 1.00 YWHAG (0.68) YWHAGGAANFKB1MAPTKDM4E
SCHEMBL3649411 0.88 ESR1 (0.53) YWHAGGAANFKB1MAPTLMNA
SCHEMBL1008790 0.88 YWHAG (0.53) YWHAGGAANFKB1MAPTKDM4E
SCHEMBL8049289 0.86 YWHAG (0.51) YWHAGGAANFKB1MAPTKDM4E
SCHEMBL3204861 0.86 YWHAG (0.51) YWHAGGAANFKB1MAPTKDM4E
SCHEMBL4029467 0.85 GAA (0.54) YWHAGGAANFKB1MAPTKDM4E
SCHEMBL137925 0.85 YWHAG (0.50) YWHAGGAANFKB1MAPTHPGD
SCHEMBL226654 0.85 YWHAG (0.50) YWHAGGAANFKB1MAPTLMNA
SCHEMBL5656071 0.85 ALDH1A1 (0.71) YWHAGGAANFKB1MAPTKDM4E
SCHEMBL17689712 0.85 YWHAG (0.50) YWHAGGAANFKB1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4134091-B1 FRACTION EXTRACT OF MELISSA OFFICINALIS LEAVES AND NOVEL PHARMACEUTICAL COMPOSITION INCLUDING SAME ANGIOLAB INC (KR) 2025-12-10 EP claimed
EP-4134091-A1 FRACTION EXTRACT OF MELISSA OFFICINALIS LEAVES AND NOVEL PHARMACEUTICAL COMPOSITION INCLUDING SAME ANGIOLAB., INC. (KR) 2023-02-15 EP claimed
WO-2007009590-A1 PROCESS FOR THE PREPARATION OF PHENOLIC COMPOUNDS DSM IP ASSETS B.V. (NL) 2007-01-25 WO claimed
US-12251370-B2 Small molecule inhibitors of the BfrB:Bfd interaction BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) 2025-03-18 US disclosed
US-20230039319-A1 DEUTERIUM-ENRICHED SUBSTITUTED PHENOXYPHENYL ACETIC ACIDS AND ACYLSULFONAMIDES DHANOA DALJIT SINGH (US) 2023-02-09 US disclosed
US-20230039319-A1 DEUTERIUM-ENRICHED SUBSTITUTED PHENOXYPHENYL ACETIC ACIDS AND ACYLSULFONAMIDES DHANOA DALJIT SINGH (US) 2023-02-09 US disclosed
US-20220031661-A1 SMALL MOLECULE INHIBITORS OF THE BFRB:BFD INTERACTION UNIVERSITY OF KANSAS 2022-02-03 US disclosed
US-20220031661-A1 SMALL MOLECULE INHIBITORS OF THE BFRB:BFD INTERACTION UNIVERSITY OF KANSAS 2022-02-03 US disclosed
US-11059771-B2 Warming sensation compounds TAKASAGO INTERNATIONAL CORPORATION (JP) 2021-07-13 US disclosed
WO-2021118826-A1 DEUTERIUM-ENRICHED SUBSTITUTED PHENOXYPHENYL ACETIC ACIDS AND ACYLSULFONAMIDES DHANOA DALJIT (US) 2021-06-17 WO disclosed
WO-2021118826-A1 DEUTERIUM-ENRICHED SUBSTITUTED PHENOXYPHENYL ACETIC ACIDS AND ACYLSULFONAMIDES DHANOA DALJIT (US) 2021-06-17 WO disclosed
EP-1494658-A1 NATURAL PHENOLIC PRODUCTS AND DERIVATIVES THEREOF FOR PROTECTION AGAINST NEURODEGENERATIVE DISEASES PULEVA BIOTECH, S.A. (ES) 2005-01-12 EP disclosed
US-20030236202-A1 Natural products and derivatives thereof for protection against neurodegenerative diseases PULEVA BIOTECH, S.A. (ES) 2003-12-25 US disclosed
US-20030225160-A1 Natural compounds and their derivatives for the prevention and treatment of cardiovascular, hepatic and renal diseases and for cosmetic applications PULEVA BIOTECH S.A. (ES) 2003-12-04 US disclosed
WO-2003082259-A1 NATURAL PHENOLIC PRODUCTS AND DERIVATIVES THEREOF FOR PROTECTION AGAINST NEURODEGENERATIVE DISEASES PULEVA BIOTECH, S.A. (ES) 2003-10-09 WO disclosed
EP-0525360-B1 Novel phenylacetamide derivatives and processes for the preparation thereof KOREA RES INST CHEM TECH (KR) 1998-03-25 EP disclosed
US-5366996-A Administering hydroxamic acids ELFORD HOWARD L (US) 1994-11-22 US disclosed
US-5242944-A Analgesics or antiinflammatory agents KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 1993-09-07 US disclosed
EP-0525360-A2 Novel phenylacetamide derivatives and processes for the preparation thereof KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 1993-02-03 EP disclosed
US-4493823-A USING CARBOXYBENZENE COMPOUND HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 1985-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225160-A1 Natural compounds and their derivatives for the prevention and treatment of cardiovascular, hepatic and renal diseases and for cosmetic applications LIPC, FABP1, NR1H2 YWHAG 1167/4885GAA 1201/4885NFKB1 933/4885
US-20230039319-A1 DEUTERIUM-ENRICHED SUBSTITUTED PHENOXYPHENYL ACETIC ACIDS AND ACYLSULFONAMIDES AGTR2, AGTR1, EDNRA YWHAG 3008/4885GAA 1263/4885NFKB1 2470/4885
US-11059771-B2 Warming sensation compounds TRPA1, TRPV1, TRPV4 YWHAG 2976/4885GAA 1976/4885NFKB1 2756/4885
US-12251370-B2 Small molecule inhibitors of the BfrB:Bfd interaction BLVRB, TFPI, ETFB YWHAG 3367/4885GAA 2498/4885NFKB1 413/4885
US-20030236202-A1 Natural products and derivatives thereof for protection against neurodegenerative diseases SNCA, HTT, PARK7 YWHAG 2059/4885GAA 149/4885NFKB1 184/4885
US-20220031661-A1 SMALL MOLECULE INHIBITORS OF THE BFRB:BFD INTERACTION BLVRB, TFPI, ETFB YWHAG 3367/4885GAA 2498/4885NFKB1 413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.